An update from FendX Technologies, Inc. ( (TSE:FNDX) ) is now available.
FendX Technologies Inc. has completed the issuance of 1,000,000 common shares under an exclusive intellectual property license agreement with Scott Smith and US BioSolutions LLC. This agreement grants FendX an exclusive license to three patent applications related to the use of Open-Cell foam sponges for cleaning surfaces and potential wound care drug delivery. Additionally, FendX has entered into a supply agreement with US BioSolutions for bulk rolls of Open-Cell foam, which FendX plans to use to create a line of eco-friendly sponge products for various markets. This strategic move is expected to enhance FendX’s market positioning and expand its product offerings in consumer and commercial cleaning markets.
More about FendX Technologies, Inc.
FendX Technologies Inc. is a Canada-based nanotechnology company focused on developing products to reduce the spread of pathogens. The company is working on film and spray products designed to protect surfaces from contamination, with its lead product being the REPELWRAP™ film. FendX collaborates with industry-leading partners, including McMaster University, and holds exclusive worldwide licenses to technology and an IP portfolio from McMaster.
YTD Price Performance: -50.0%
Average Trading Volume: 73,449
Technical Sentiment Signal: Buy
Find detailed analytics on FNDX stock on TipRanks’ Stock Analysis page.